bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 22.4% in January

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 40,326 shares, a decline of 22.4% from the December 31st total of 51,967 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 73,792 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 73,792 shares, the short-interest ratio is presently 0.5 days. Approximately 0.9% of the company’s stock are short sold.

bioAffinity Technologies Stock Performance

Shares of BIAF stock traded down $0.03 on Friday, hitting $1.14. 53,502 shares of the stock traded hands, compared to its average volume of 61,808. The company’s fifty day moving average is $1.36 and its 200 day moving average is $4.09. bioAffinity Technologies has a 1-year low of $1.11 and a 1-year high of $46.53. The company has a market capitalization of $5.13 million, a PE ratio of -0.05 and a beta of 2.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.64.

bioAffinity Technologies (NASDAQ:BIAF) last issued its earnings results on Friday, November 14th. The company reported ($2.70) earnings per share for the quarter, hitting analysts’ consensus estimates of ($2.70). bioAffinity Technologies had a negative net margin of 217.45% and a negative return on equity of 425.87%. The company had revenue of $1.45 million for the quarter, compared to analysts’ expectations of $1.41 million.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Sabby Management LLC bought a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 242,757 shares of the company’s stock, valued at approximately $719,000. bioAffinity Technologies comprises approximately 0.8% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned approximately 6.68% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, bioAffinity Technologies currently has an average rating of “Reduce”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.